Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle C Fox

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
American Journal of Obstetrics and Gynecology|August 24, 2002
Early surgical abortion: efficacy and safetyMaureen E Paul, Caroline M Mitchell, Angela J Rogers, et al.
Contraception|September 27, 2015
Six-month and 1-year continuation rates following postpartum insertion of implants and intrauterine devicesIrene Woo, Sara Seifert, Dacia Hendricks, et al.
Obstetrics and Gynecology|May 4, 2004
A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortionMitchell D Creinin, Michelle C Fox, Stephanie Teal, et al.
Contraception|November 16, 2018
A phase 2b multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of vaginal rings containing nomegestrol acetate or etonogestrel and 17β-estradiol in the treatment of women with primary dysmenorrheaMichelle C Fox, Christine Klipping, Allison Martin Nguyen, et al.
Contraception|December 8, 2010
Immediate placement of intrauterine devices after first and second trimester pregnancy terminationMichelle C Fox, Julia Oat-Judge, Kathryn Severson, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
MicroRNA miR-125a controls hematopoietic stem cell numberShangqin Guo, Jun Lu, Rita Schlanger, et al.
The Journal of Clinical Endocrinology and Metabolism|March 11, 2022
Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic HypogonadismR Ravi Shankar, Suneri Shah, Hee-Koung Joeng, et al.
The Journal of Infectious Diseases|May 29, 2026
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNATracy L Diamond, Anjana Grandhi, Monica Fuszard, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trialJean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
American Journal of Obstetrics and Gynecology|August 24, 2002
Early surgical abortion: efficacy and safetyMaureen E Paul, Caroline M Mitchell, Angela J Rogers, et al.
Contraception|September 27, 2015
Six-month and 1-year continuation rates following postpartum insertion of implants and intrauterine devicesIrene Woo, Sara Seifert, Dacia Hendricks, et al.
Obstetrics and Gynecology|May 4, 2004
A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortionMitchell D Creinin, Michelle C Fox, Stephanie Teal, et al.
Contraception|November 16, 2018
A phase 2b multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of vaginal rings containing nomegestrol acetate or etonogestrel and 17β-estradiol in the treatment of women with primary dysmenorrheaMichelle C Fox, Christine Klipping, Allison Martin Nguyen, et al.
Contraception|December 8, 2010
Immediate placement of intrauterine devices after first and second trimester pregnancy terminationMichelle C Fox, Julia Oat-Judge, Kathryn Severson, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
MicroRNA miR-125a controls hematopoietic stem cell numberShangqin Guo, Jun Lu, Rita Schlanger, et al.
The Journal of Clinical Endocrinology and Metabolism|March 11, 2022
Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic HypogonadismR Ravi Shankar, Suneri Shah, Hee-Koung Joeng, et al.
The Journal of Infectious Diseases|May 29, 2026
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNATracy L Diamond, Anjana Grandhi, Monica Fuszard, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trialJean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Pageof 3